Coxa PLC

Medicine & Life Sciences

1. Arthroplasty 100%
2. Hip 86%
3. Knee Replacement Arthroplasties 73%
4. Knee 41%
5. Metals 30%
6. Finland 30%
7. Joints 27%
8. Chondrocytes 24%
9. Patellar Dislocation 24%
10. Cobalt 23%
11. Chromium 21%
12. Incidence 19%
13. Osteoarthritis 19%
14. Polyethylene 19%
15. Confidence Intervals 17%
16. Infections 16%
17. Survival 15%
18. Knee Joint 15%
19. Replacement Arthroplasties 14%
20. High-Volume Hospitals 11%
21. Tacrine 11%
22. Hip Joint 10%
23. Reoperation 9%
24. Spinal Anesthesia 9%
25. RNA-Seq 9%
26. Pain 9%
27. Retrospective Studies 9%
28. Tibia 8%
29. melflufen 8%
30. Randomized Controlled Trials 8%
31. Head 8%
32. Ions 8%
33. Traumatic Brain Injury 7%
34. Patella 7%
35. Periprosthetic Fractures 7%
36. Mesenchymal Stem Cells 7%
37. Dexamethasone 7%
38. Bone and Bones 6%
39. Anti-Bacterial Agents 6%
40. Patient Reported Outcome Measures 6%
41. Cohort Studies 6%
42. Analgesics 6%
43. Propensity Score 6%
44. Neoprene 6%
45. Thigh 6%
46. Therapeutics 6%
47. Hallux Rigidus 6%
48. Knee Osteoarthritis 6%
49. Exercise 6%
50. Vitamin E 6%
51. Population 6%
52. Genes 5%
53. Articular Range of Motion 5%
54. Bone Marrow 5%
55. Osseointegration 5%
56. Craniotomy 5%
57. Phenotype 5%
58. Ankyrins 5%
59. Comorbidity 5%
60. Scandinavian and Nordic Countries 5%
61. Interleukin-1 5%
62. Prospective Studies 5%
63. Databases 5%
64. Ibuprofen 5%
65. Hallux Valgus 5%
66. Metatarsophalangeal Joint 5%
67. Thermometers 5%
68. Arthritis 5%
69. Osteolysis 5%
70. Femoral Fractures 5%
71. Equivalence Trials 5%
72. Tendon Injuries 5%
73. compound A 12 5%
74. Cartilage 5%
75. Pandemics 5%